Erasca(ERAS) - 2024 Q3 - Quarterly Results

Financial Position - Cash, cash equivalents, and marketable securities totaled $463.3 million as of September 30, 2024, up from$322.0 million as of December 31, 2023, providing a runway into H1 2027[5] - Total assets increased to $528.9 million as of September 30, 2024, compared to$395.3 million as of December 31, 2023[9] - Accumulated deficit reached $(735.4) million as of September 30, 2024, compared to$(606.0) million at the end of 2023[9] Expenses - Research and Development (R&D) expenses increased to $27.6 million for Q3 2024, compared to$25.2 million for Q3 2023, driven by clinical trial and preclinical study costs[5] - General and Administrative (G&A) expenses were $9.6 million for Q3 2024, slightly up from$9.4 million in Q3 2023[6] Net Loss - Net loss for Q3 2024 was $31.2 million, or$(0.11) per share, compared to a net loss of $30.4 million, or$(0.20) per share, in Q3 2023[6] Clinical Trials and Development - The SEACRAFT-2 Phase 3 trial is expected to report randomized dose optimization data in 2025, targeting NRAS-mutant melanoma[4] - IND filings for ERAS-4001 (pan-KRAS inhibitor) are anticipated in Q1 2025, with initial Phase 1 data expected in 2026[4] - IND filing for ERAS-0015 (pan-RAS molecular glue) is expected in H1 2025, with initial Phase 1 data also anticipated in 2026[4] - The company has confirmed potential best-in-class profiles for both ERAS-0015 and ERAS-4001, supporting their development[2]